skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

First-line treatment of acute lymphoblastic leukemia with pegasparaginase

Review

(3481) Views  (1079) Full article downloads

Authors: Riccardo Masetti, Andrea Pession

Published Date July 2009 Volume 2009:3 Pages 359 - 368
DOI: http://dx.doi.org/10.2147/BTT.S3295

Riccardo Masetti, Andrea Pession

Pediatric Oncology and Hematology Unit “Lalla Seràgnoli”, University of Bologna, Bologna, Italy

Abstract: Acute lymphoblastic leukemia (ALL) accounts for almost 4000 cases annually in the United States, approximately two thirds of which are in children and adolescents. Treatment results of ALL have improved considerably in the past decade, due to an optimal stratification of patients and a rational use of different antileukemic agents among which L-asparaginase (L-ASNase) plays a fundamental role. This drug has been used in pediatric ALL chemotherapy protocols for almost 3 decades. In the 1970s and 1980s a chemically modified form of this enzyme called pegasparaginase (PEG-ASNase) was rationally synthesized to decrease immunogenicity of the enzyme and prolong its half-life. The different advantages of PEG-ASNase have been demonstrated in many clinical studies, the last of which underline the utility of this drug in front-line therapy of ALL. In this review, we discuss the pharmacological advantages and clinical potential of PEG-ASNase and its important use in first-line treatment of ALL.

Keywords: pegasparaginase, acute, lymphoblastic leukemia, pegylation






 

Other articles by Professor Andrea Pession



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Tuberculosis in children undergoing hemodialysis
Palliative treatment of malignant ascites: profile of catumaxomab
Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
Use of clofarabine for acute childhood leukemia
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed